No Data
Zhejiang Jiuzhou Pharmaceutical (603456.SH): The approval notice for the market launch application of Fumarate Vonoprazan as a Chemical Raw Materials has been received.
Gelonghui, April 24丨Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that its wholly-owned subsidiary Zhejiang Jiuzhou Pharmaceutical Technology Co., Ltd. has received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration for Fumaric Acid Vorinostat. Fumaric Acid Vorinostat is primarily used to treat acid-related diseases, including reflux esophagitis (RE), gastric ulcers, and duodenal ulcers.
Zhejiang Jiuzhou Pharmaceutical (603456.SH): The holding subsidiary has obtained the Pharmaceutical registration certificate.
On April 22, Gelonghui reported that Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that its holding subsidiary, Zhejiang Jiuzhou Biomedical Co., Ltd. (referred to as "Jiuzhou Biomedical"), received the pharmaceutical registration certificate for Lacosamide Tablets issued by the National Medical Products Administration. Lacosamide Tablets are suitable for adjunctive treatment of partial seizures in epilepsy patients aged 4 years and older. Obtaining the pharmaceutical registration certificate for Lacosamide Tablets further enriches the company's product pipeline and helps enhance the market competitiveness of the company's products. The above matters will not have a significant impact on the company's performance in the short term.
Zhejiang Jiuzhou Pharmaceutical's (SHSE:603456) Soft Earnings Don't Show The Whole Picture
Jiuzhou Pharmaceutical: Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Report for the first quarter of 2025
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Report for the first quarter of 2025
Zhejiang Jiuzhou Pharmaceutical (603456.SH): In the first quarter, the net income was 0.25 billion yuan, a year-on-year growth of 5.68%.
On April 14, Glonghui reported that Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced its first quarter report, with revenue of 1.49 billion yuan, a year-on-year increase of 0.98%. The net income attributable to shareholders of the listed company was 0.25 billion yuan, a year-on-year increase of 5.68%. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.25 billion yuan, representing a year-on-year increase of 7.17%.
Those Who Invested in Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Five Years Ago Are up 174%
